Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +210,975.57%
#2 Beta Finance Beta Finance +8,979.03%
#3 Tribe Tribe +73.83%
#4 Orochi Network Orochi Network +53.40%
#5 Chainbase Chainbase +40.85%
#6 BabyBoomToken BabyBoomToken +34.25%
#7 Block Street Block Street +31.59%
#8 Chrema Coin Chrema Coin +28.62%
#9 Freysa AI Freysa AI +26.78%
#10 B3 (Base) B3 (Base) +25.98%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Classifica tra le azioni #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Prezzo delle azioni
$0.00244926
Capitalizzazione di mercato
$51.67K
Variazione (1 giorno)
5.88%
Variazione (1 anno)
110.15%
Paese
GB
Scambia Nuformix plc (NFX)

Categoria

Healthcare
Rapporto P/B per Nuformix plc (NFX)
Rapporto P/B al March 2026 TTM: 5.52
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Nuformix plc, il rapporto P/B attuale (TTM) è 5.52. Alla fine del 2024, era pari a 0.64.
Storico del rapporto P/B per Nuformix plc da 2014 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
2026 (TTM) 5.52 6.74%
2025 5.17 703.62%
2024 0.64 44.29%
2023 0.45 -63.79%
2022 1.23 -46.40%
2021 2.30 -42.90%
2020 4.02 28.15%
2019 3.14 93.67%
2018 1.62 -108.69%
2017 -18.66 -793.31%
2016 2.69 0.00%
2014 0.00 0.00%
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 5.6573 2.51%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3842 15.68%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.4551 -55.51%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.364 -20.92%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5504 -53.79%
AU